CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 59-62

  Weeratna, Risini ^a,c   Comanita, Lacrimioara ^b   Davis, Heather L ^a  

^a Coley Pharmaceutical Group ^*  (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Coley Pharmaceutical Cananda ^*  (Canada)

Author keywords

Antigen dose; CpG containing oligodeoxynucleotide; Vaccine

Indexed keywords

CYTOSINE; DINUCLEOTIDE; GUANINE; HEPATITIS B SURFACE ANTIGEN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; RECOMBINANT HEPATITIS B VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; MOUSE STRAIN; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CPG ISLANDS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; VACCINES;

ANIMALIA;

EID: 0037324369     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.01135.x     Document Type: Article

References (27)

1. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 1997; 15: 297-322.
2. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit. Rev. Immunol. 1998; 18: 275-303.
3. Ruedl C, Bachmann MF, Kopf M. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur. J. Immunol. 2000; 30: 2056-64.
4. Cookson OCM, Moffatt MF. Asthma: An epidemic in the absence of infection? Science 1997; 275: 41-2.
5. Kline JN. Effects of CpG DNA on Th1/Th2 balance in asthma. Curr. Top Microbiol. Immunol. 2000; 247: 211-25.
6. Rook GA, Zumla A. Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet 1997; 349: 1831-3.
7. Shaheen S. Shots in the desert and Gulf war syndrome. Evidence that multiple vaccinations during deployment are to blame is inconclusive. BMJ 2000; 320: 1351-2.
8. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J. Autoimmun. 2000; 14: 1-10.
9. Freidag BL, Melton GB, Collins F et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 2000; 68: 2948-53.
10. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin. Chem. Lab. Med. 1999; 37: 199-204.
11. McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant. Vaccine 1999; 18: 231-7.
12. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998; 16: 1216-24.
13. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 1999; 67: 3719-26.
14. Walker PS, Scharton-Kersten T, Krieg AM et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc. Natl Acad. Sci. USA 1999; 96: 6970-5.
15. von Hunolstein C, Teloni R, Mariotti S, Recchia S, Orefici G, Nisini R. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int. Immunol. 2000; 12: 295-303.
16. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 1998; 95: 15553-8.
17. Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000; 19: 530-7.
18. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998; 160: 870-6.
19. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755-62.
20. Ballas ZK, Rasmussen WL, Krieg AM. Induction of natural killer activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 1996; 157: 1840-5.
21. Cowdery JS, Chace JH, Yi A-K, Krieg AM. Bacterial DNA induces NK cells to produce interferon-γ in vivo and increases the toxicity of lipopolysaccharide. J. Immunol. 1996; 156: 4570-5.
22. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol. 1996; 167: 72-8.
23. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA 1996; 93: 2879-83.
24. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist C, Davis HL. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. Fems. Immunol. Med. Microbiol. 2001; 30: 241-7.
25. World Health Organization. Report on infectious diseases: Removing obstacles to healthy development. World Health Organization, 1999; p WHO/CDC/99.1.
26. Hartmann G, Weeratna RD, Ballas ZK et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000; 164: 1617-24.
27. Davis HLCC, Morris ML, Efler SM, Cameron DW, Heathcote J. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Paper presented at: The Third Annual Conference on Vaccine Research; S25: 47, 2000.